Infusional ECarboF for Advanced Breast Cancer
Author Information
Author(s): H Bonnefoi, IE Smith, MER O'Brien, MT Seymour, TJ Powles, WH Allum, S Ebbs, M Baum
Primary Institution: Royal Marsden Hospital
Hypothesis
Can substituting carboplatin for cisplatin in the infusional ECF regimen improve treatment outcomes for patients with metastatic or locally advanced breast cancer?
Conclusion
The infusional ECarboF regimen is highly active and well-tolerated for treating advanced breast cancer, showing similar efficacy to the original ECF regimen but with reduced toxicity.
Supporting Evidence
- The overall response rate was 81%, with a complete response rate of 17% in metastatic patients.
- Severe grade 3/4 toxicity was low, indicating good tolerability of the regimen.
- Median survival for metastatic disease was 14 months, suggesting effective treatment.
- Patients were treated in an outpatient setting, enhancing convenience.
Takeaway
This study tested a new cancer treatment that uses a different drug to make it easier for patients. It worked well and caused fewer side effects.
Methodology
Patients with metastatic or locally advanced breast cancer received a regimen of 5-fluorouracil, epirubicin, and carboplatin over six courses, with response rates assessed after treatment.
Potential Biases
Potential selection bias due to non-randomized design.
Limitations
The study was not randomized and had a relatively small sample size.
Participant Demographics
Median age was 48 years, with 26 premenopausal and 26 peri- or post-menopausal patients.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 67-90%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website